Two Directors at Seagen Inc sold/sold after exercising options 19,405 shares at between 213.010USD and 213.324USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the co...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
SEATTLE GENETICS (US), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date September 18, 2020, the closing price was USD 180.94 and its potential was estima...
S&P 500 Breaking To New Highs We like to say that new highs are not a sell signal, and this time is no different. With the S&P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of the uptrends that began in March... see charts below. Therefore, we continue to have a bullish outlook and we believe the path of least resistance remains higher. · Sector Relative Strength Rankings & Weighting Recommendations. Seve...
The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom†we laid out our gameplan and what we need to see before having confidence that equity markets ar...
MSCI ACWI, STOXX 600 Breaking Out The market continues to feed off of optimism surrounding the US-China “phase one†trade deal. Boris Johnson's UK election victory has added an additional tailwind, particularly in the UK and Europe, where the UK's FTSE 250 and the STOXX Europe 600 indexes are breaking out to all-time highs. At some point the euphoria is likely to wear off, but with continued global bullish developments, it remains our belief that pullbacks should be bought and that global e...
Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has per...
Seattle Genetics reported revenue of $218 million, up 28% from last year. Adcetris sales of $159 million in the U.S. and Canada were up 30% from last year and 17% sequentially, which represents solid growth that helps offset the company's weaker first quarter. Adcetris, which is used to treat classical Hodgkin's lymphoma and anaplastic large cell lymphoma, remains the company's key driver, and we anticipate steady double-digit growth for the next several years due to Adcetris' solid efficacy and...
Seattle Genetics reported revenue of $218 million, up 28% from last year. Adcetris sales of $159 million in the U.S. and Canada were up 30% from last year and 17% sequentially, which represents solid growth that helps offset the company's weaker first quarter. Adcetris, which is used to treat classical Hodgkin's lymphoma and anaplastic large cell lymphoma, remains the company's key driver, and we anticipate steady double-digit growth for the next several years due to Adcetris' solid efficacy and...
We think Seattle Genetics' next-generation cancer therapy Adcetris and robust pipeline, which are based on its proprietary antibody-drug conjugate, or ADC, technology platform, make it stand out among its emerging biotech peers. The firm's leading ADC technology has allowed it to develop an internal pipeline of innovative cancer treatments and become the partner of choice for leading oncology players. The technology improves the potency and safety of cancer-targeting monoclonal antibodies by lin...
Seattle Genetics reported revenue of $195 million, slightly below our expectations, with Adcetris sales seasonably softer in the first quarter. Net Adcetris sales of $135 million in the United States and Canada represent a 42% increase from last year, and we are maintaining our forecast of about $610 million for the full year, which falls at the lower end of management's maintained guidance. Operating expenses were mostly in line with our expectations, with costs and expenses from Seattle's mult...
Seattle Genetics reported revenue of $195 million, slightly below our expectations, with Adcetris sales seasonably softer in the first quarter. Net Adcetris sales of $135 million in the United States and Canada represent a 42% increase from last year, and we are maintaining our forecast of about $610 million for the full year, which falls at the lower end of management's maintained guidance. Operating expenses were mostly in line with our expectations, with costs and expenses from Seattle's mult...
Seattle Genetics reported revenue of $195 million, slightly below our expectations, with Adcetris sales seasonably softer in the first quarter. Net Adcetris sales of $135 million in the United States and Canada represent a 42% increase from last year, and we are maintaining our forecast of about $610 million for the full year, which falls at the lower end of management's maintained guidance. Operating expenses were mostly in line with our expectations, with costs and expenses from Seattle's mult...
The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&P 500 and roughly 1,000 on the S&P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher. This constructive outlook is supported by the theme...
We don't anticipate a material change to our fair value estimate for no-moat Seattle Genetics following fourth-quarter results. Fourth-quarter revenue of over $174 million was slightly higher than our expectations, mostly due to better-than-expected Adcetris sales by partner Takeda, resulting in $83 million in royalty revenue, up 26% from last year. However, bottom-line results were lower than our expectations and analyst consensus. An $18 million inventory write-off bumped up cost of sales to o...
We don't anticipate a material change to our fair value estimate for no-moat Seattle Genetics following fourth-quarter results. Fourth-quarter revenue of over $174 million was slightly higher than our expectations, mostly due to better-than-expected Adcetris sales by partner Takeda, resulting in $83 million in royalty revenue, up 26% from last year. However, bottom-line results were lower than our expectations and analyst consensus. An $18 million inventory write-off bumped up cost of sales to o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.